Coca-Cola’s Costa Coffee Sale Faces Uncertainty as Talks With TDR Capital Hit Snag 
SUPERFORTUNE Launches AI-Powered Mobile App, Expanding Beyond Web3 Into $392 Billion Metaphysics Market 
HSBC’s $13.6 Billion Take-Private Offer for Hang Seng Bank Gains Board Backing 
United Airlines Tokyo-Bound Flight Returns to Dulles After Engine Failure 
Nvidia Weighs Expanding H200 AI Chip Production as China Demand Surges 
FAA Unveils Flight Plan 2026 to Strengthen Aviation Safety and Workforce Development 
Ford Takes $19.5 Billion Charge as EV Strategy Shifts Toward Hybrids 
Intel’s Testing of China-Linked Chipmaking Tools Raises U.S. National Security Concerns 
Korea Zinc to Build $7.4 Billion Critical Minerals Refinery in Tennessee With U.S. Government Backing 
FDA Says No Black Box Warning Planned for COVID-19 Vaccines Despite Safety Debate 
Woolworths Faces Fresh Class Action Over Alleged Underpayments, Shares Slide 
Coca-Cola’s Proposed Sale of Costa Coffee Faces Uncertainty Amid Price Dispute 
Shell M&A Chief Exits After BP Takeover Proposal Rejected 
Azul Airlines Wins Court Approval for $2 Billion Debt Restructuring and New Capital Raise 
SpaceX Insider Share Sale Values Company Near $800 Billion Amid IPO Speculation 
Mizuho Raises Broadcom Price Target to $450 on Surging AI Chip Demand 
Trello Outage Disrupts Users as Access Issues Hit Atlassian’s Work Management Platform 
STEVENSON, Md., Dec. 28, 2016 -- The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of New York on behalf of purchasers of Endo International plc (Nasdaq:ENDP) (“Endo” or the “Company”) securities during the period between September 28, 2015 and November 2, 2016, inclusive (the “Class Period”). Investors who wish to become proactively involved in the litigation have until January 6, 2017 to seek appointment as lead plaintiff.
If you wish to choose counsel to represent you and the Class, you must apply to be appointed lead plaintiff and be selected by the Court. The lead plaintiff will direct the litigation and participate in important decisions including whether to accept a settlement for the Class in the action. The lead plaintiff will be selected from among applicants claiming the largest loss from investment in Endo securities during the Class Period. Members of the Class will be represented by the lead plaintiff and counsel chosen by the lead plaintiff. No class has yet been certified in the above action.
The complaint accuses the defendants of violations of the Securities Exchange Act of 1934 by virtue of the defendants’ failure to disclose during the Class Period that Endo’s subsidiary, Par Pharmaceutical, had colluded with several of its industry peers to fix generic drug prices, which constituted a violation of federal antitrust laws, and Endo’s revenues were in part the result of illegal conduct.
According to the complaint, following November 3, 2016 media reports that U.S. prosecutors were considering filing criminal charges by the end of 2016 against Par Pharmaceutical and several other pharmaceutical companies for unlawfully colluding to fix generic drug prices, the value of Endo shares declined significantly.
If you have suffered a loss in excess of $100,000 from investment in Endo securities purchased on or after September 28, 2015 and held through the revelation of negative information during and/or at the end of the Class Period and would like to learn more about this lawsuit and your ability to participate as a lead plaintiff, without cost or obligation to you, please visit our website at http://www.browerpiven.com/currentsecuritiescases.html. You may also request more information by contacting Brower Piven either by email at [email protected] or by telephone at (410) 415-6616. Brower Piven also encourages anyone with information regarding the Company’s conduct during the period in question to contact the firm, including whistleblowers, former employees, shareholders and others.
Attorneys at Brower Piven have extensive experience in litigating securities and other class action cases and have been advocating for the rights of shareholders since the 1980s. If you choose to retain counsel, you may retain Brower Piven without financial obligation or cost to you, or you may retain other counsel of your choice. You need take no action at this time to be a member of the class.
CONTACT: Charles J. Piven Brower Piven, A Professional Corporation 1925 Old Valley Road Stevenson, Maryland 21153 Telephone: 410-415-6616 [email protected]
